logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Hepatitis C Chronic

    Medications for Hepatitis C Chronic

    FiltersReset Filters
    3 results

    • mavyret

      (Glecaprevir and Pibrentasvir)
      AbbVie Inc.
      Usage: MAVYRET is indicated for treating chronic hepatitis C virus (HCV) genotypes 1-6 in patients aged 3 years and older, with or without compensated cirrhosis. It is also approved for HCV genotype 1 patients who have previously received specific antiviral treatments.

    • ribavirin

      (Ribavirin)
      Aurobindo Pharma Limited
      Usage: Ribavirin capsules, in combination with interferon alfa-2b (pegylated and nonpegylated), are indicated for treating Chronic Hepatitis C (CHC) in patients aged 3 years and older with compensated liver disease. Combination with PegIntron is preferred for better response rates. Long-term treatment safety and efficacy beyond one year are not established.

    • vosevi

      (SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR)
      Gilead Sciences, Inc.
      Usage: VOSEVI is indicated for treating adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have specific genotypes and have previously been treated with certain HCV regimens, particularly those including an NS5A inhibitor.